PLG-101 (EMOTION Program)

About Polygon Therapeutics

Polygon Therapeutics is a Paris-based, preclinical-stage biotech targeting the significant unmet medical need in cardiovascular diseases through immunotherapies. Its lead asset, PLG-101, is a human anti-CD8 monoclonal antibody shown in nonclinical models to reduce infarct size by 60% and improve heart function by 25% following a heart attack. The company is built on strong foundational science from its co-founders, including a leading clinician-scientist, and is positioned at the forefront of the nascent but promising cardio-immunology field. Its strategy involves advancing PLG-101 towards clinical trials while building out a broader discovery platform.

Therapeutic Areas